A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
News|Articles|April 14, 2025
Tirzepatide Surges, Overtakes Older Drugs in Diabetes, Obesity Care
Author(s)Maggie L. Shaw
Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.
Advertisement
Advertisement
Researchers have used the US launch of tirzepatide, a dual glucagon-like peptide-1 receptor agonist (GLP-1 RA) and glucose-dependent insulinotropic polypeptide receptor agonist, as the dividing point to study trends in the use of glucose-lowering medications (GLMs) and weight-lowering medications (WLMs) using commercial insurance claim data.
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Advertisement
Advertisement